Global Human Embryonic Stem Cell Laws and Policies and Their Influence on Stem Cell Tourism
By Nishakanthi Gopalan et al.,
Biotechnology Law Report
| 10. 09. 2018
Abstract
Stem cell (SC) technology has spurred many debates among experts which highlight both the deficiency of current regulation and the growing need for better oversight. The benefit of better regulating SC technology is easily understood by studying the variety of laws and policies available. Previous compilations, last published in 2009, are outdated, calling for an update. Therefore, this study aims to bring up to date the laws and policies relating to human embryonic stem cells (HESC) and to identify emerging trends in regulation. The review of numerous legal documents, including bills and legislation, accessed through official government portals, found that all developed countries have sound legislation promoting research. While some developed nations have gaps within their otherwise-sound regulation, a more pressing issue is growing travel for treatment (“SC tourism”) to developing and under-developed countries where SC technology is under- or unregulated. Therefore, SC tourism is no longer a country issue; rather, it is a universal dilemma requiring international effort for a resolution.
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...